Kezar Life Sciences, Inc. - KZR STOCK NEWS

Kezar Life Sciences (Nasdaq: KZR) announced upcoming presentations at two virtual investor conferences. The first event is the Jefferies Virtual London Healthcare Conference on November 18, 2020, featuring a fireside chat with CEO John Fowler, CSO Christopher Kirk, and CMO Noreen R. Henig. The second presentation will be at the 2020 Evercore ISI HealthCONx Conference on December 3, 2020, led by CEO John Fowler. Both presentations will be webcast live and archived on the company's website for 90 days.

Kezar Life Sciences, a clinical-stage biotechnology firm, presented promising data on KZR-616, an innovative immunoproteasome inhibitor, during the American College of Rheumatology Annual Meeting. Dr. Richard Furie's presentation revealed updated safety and efficacy signals for KZR-616 in systemic lupus erythematosus (SLE) with no new safety concerns. The drug displayed encouraging trends in disease activity scores and has been well tolerated during trials. Additionally, preclinical findings suggest KZR-616 might significantly aid in treating inflammatory myopathies. The ongoing clinical studies include MISSION and PRESIDIO trials.

Kezar Life Sciences, a clinical-stage biotechnology firm, has announced that the FDA has granted Orphan Drug Designation for KZR-616, targeting polymyositis (PM) and dermatomyositis (DM). PM and DM are rare autoimmune diseases affecting up to 51,000 and 71,000 individuals in the U.S., respectively. KZR-616 is a first-in-class selective immunoproteasome inhibitor aimed at addressing the underlying causes of these diseases. The designation may offer significant benefits, including marketing exclusivity and tax credits. A Phase 2 trial for KZR-616 is currently enrolling patients.

Kezar Life Sciences (Nasdaq: KZR) announced six presentations at four medical conferences, highlighting KZR-616, a selective immunoproteasome inhibitor, and its potential in treating immune-mediated diseases. Key presentations include interim results from the MISSION Phase 1b study on systemic lupus erythematosus (SLE) and preclinical data on KZR-616's mechanism of action. The company is also showcasing KZR-261, a protein secretion inhibitor, expected to enter IND submission for solid tumors in early 2021. These advancements underline Kezar's commitment to developing innovative therapies.

Kezar Life Sciences (KZR) has announced a public offering of 7,590,909 shares of common stock at a price of $5.50 per share, along with 909,091 pre-funded warrants priced at $5.499, aiming for gross proceeds of $46.7 million. A 30-day option for underwriters to purchase an additional 1,275,000 shares has been granted. Proceeds will mostly fund R&D and potential acquisitions. The offering is set to close on June 11, 2020, subject to standard closing conditions. The offering is registered under an SEC effective shelf registration statement.

Kezar Life Sciences, Inc. (Nasdaq: KZR) announced promising results from its Phase 1b study of KZR-616 for treating systemic lupus erythematosus (SLE) and lupus nephritis. Among two lupus nephritis patients, both experienced over 50% reduction in proteinuria. Overall, the study showed improvements in seven disease activity measures, indicating positive exploratory efficacy data. The safety profile of KZR-616 was favorable, with no treatment discontinuations reported. Encouraged by the results, Kezar aims to expedite the development of KZR-616 for severe autoimmune diseases.

Kezar Life Sciences announced that its executive team will participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference on June 4, 2020, at 1:30 PM EDT. The event will be accessible via live webcast through the company's website, with an archived replay available for 90 days post-conference. Kezar focuses on innovative therapies for autoimmune diseases and cancer, with candidates like KZR-616 and KZR-261 in development.

Kezar Life Sciences (Nasdaq: KZR) announced significant presentations at major upcoming scientific conferences, highlighting their innovative therapeutic programs. Three abstracts have been accepted, showcasing the preclinical data for KZR-261 targeting solid tumors and the promising clinical data for KZR-616 in treating severe autoimmune diseases. Notably, these presentations include details about clinical trials and findings that underscore the potential of these compounds in their respective therapeutic areas.

Kezar Life Sciences (KZR) announced key updates in its Q1 2020 financial results and corporate activities. Noreen R. Henig, MD, has been appointed as Chief Medical Officer, enhancing the leadership team. The company reported cash and equivalents of $123 million as of March 31, 2020, a notable increase from $78.2 million in Q4 2019. Ongoing clinical trials for KZR-616 are active, despite anticipated delays due to COVID-19. Additionally, KZR-261's IND submission is on track for Q1 2021, with new data presentation planned at ASCO 2020.